Genetic Signatures (GSS) Q1 2027 TU earnings summary

Executive summary

• Q1 FY2027 delivered lower operating costs and cash outflow following the Q4 FY2026 restructure; quarter-end cash and term deposits were $20.9m, with no debt.

• Progress included commercial testing at Hvidovre Hospital, APAC market development and agreement on principal terms for a proposed all-scrip merger with Microba.

Financial highlights

• Q1 sales were $4.0m versus $5.4m in Q1 FY2026; customer receipts were $4.2m.

• Net operating cash outflow was $1.0m, versus $3.4m in Q4 FY2026 ($2.6m excluding $0.8m one-off redundancy payments) and $2.1m in Q1 FY2026.

• Operating expenses, excluding cost of materials, were $4.0m, down 30% from $5.7m in Q1 FY2026; staff costs were $2.5m versus $3.8m YoY.

• Quarter-end cash and term deposits were $20.9m, comprising $7.9m in bank balances and $13.0m in term deposits; cash and cash equivalents were $20.931m.

Outlook and guidance

• Annualised operational cost savings of up to $5m remain the target following the restructure.

• Cash outflows are expected to vary in coming months due to one-off product development costs and seasonal revenue changes.

• Priorities include growing EasyScreen sales, broadening the testing menu, building on Hvidovre momentum and pursuing APAC opportunities, with disciplined capital deployment and improved unit economics.